R-Fluoxetine

R-Fluoxetine

SCHEMBL3905325

CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A4

The experimentally established mechanism targets of R-Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 12/20 1.00
SLC6A2 P23975 5/20 1.00
MEN1 O00255 4/20 1.00
LMNA P02545 4/20 1.00
KMT2A Q03164 4/20 1.00
SLC6A3 Q01959 4/20 1.00
PMP22 Q01453 3/20 1.00
CYP3A4 P08684 2/20 1.00
HTR2C P28335 2/20 1.00
ALDH1A1 P00352 1/20 1.00
APEX1 P27695 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
GMNN O75496 1/20 1.00
HPGD P15428 1/20 1.00
GPR183 P32249 1/20 1.00
APLNR P35414 1/20 1.00
CX3CR1 P49238 1/20 1.00
GPR65 Q8IYL9 1/20 1.00
GPR35 Q9HC97 1/20 1.00
CYP2D6 P10635 3/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoxetine SCHEMBL3399076 1.00 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL33384 1.00 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL7081402 1.00 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL56333 1.00 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL8911991 1.00 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL33947 0.99 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL570572 0.99 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL8467346 0.99 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
Fluoxetine SCHEMBL8353 0.99 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A
R-Fluoxetine SCHEMBL1200433 0.99 SLC6A4 (1.00) SLC6A4SLC6A2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114699374-B Fluoxetine hydrochloride solid preparation special for dogs and cats and preparation and application thereof 佛山市南海东方澳龙制药有限公司 2024-02-20 CN disclosed
CN-117143245-A Anti-fluoxetine antibodies or antigen binding fragments thereof and uses thereof 杭州旭科生物技术有限公司 2023-12-01 CN disclosed
US-20220249404-A1 COMPOSITION CONTAINING FLUOXETINE AND VITAMIN D3 OR ITS DERIVATIVES, AND APPLICATION THEREOF NANJING RUIYING RUNZE BIOPHARMACEUTICAL TECHNOLOGY CO., INC. (CN) 2022-08-11 US disclosed
CN-114699374-A Fluoxetine hydrochloride solid preparation special for cats and dogs as well as preparation and application thereof 佛山市南海东方澳龙制药有限公司 2022-07-05 CN disclosed
CN-112007039-B A pharmaceutical composition containing fluoxetine and vitamin D3Or derivatives thereof, and uses thereof 南京睿鹰润泽生物医药科技有限公司 2022-05-27 CN disclosed
CN-110711198-B Application of D-mannose in preparation of antidepressant 山东大学 2022-03-15 CN disclosed
US-7485754-B2 Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers APOTEX PHARMACHEM INC. (CA) 2009-02-03 US disclosed
WO-2007006132-A1 AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS APOTEX PHARMACHEM INC. (CA) 2007-01-18 WO disclosed
US-20070010678-A1 Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers APOTEX PHARMACHEM INC. 2007-01-11 US disclosed
EP-0612242-B1 USE OF THE PURE S(+) ISOMER OF FLUOXETINE FOR THE PREPARATION OF A MEDICAMENT AGAINST MIGRAINE HEADACHE SEPRACOR INC (US) 2003-07-09 EP disclosed
EP-1208838-A2 Pure S(+)isomer fluoxetine Sepracor Inc. (US) 2002-05-29 EP disclosed
WO-2000068182-A1 PROCESS FOR CRYSTALLIZING (R)-FLUOXETINE HYDROCHLORIDE ELI LILLY AND COMPANY (US) 2000-11-16 WO disclosed
US-5589511-A Method for treating migraine headaches using optically pure S(+) fluoxetine SEPRACOR INC. (US) 1996-12-31 US disclosed
WO-1995028152-A1 METHODS AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER DISORDERS USING OPTICALLY PURE S(+) FLUOXETINE SEPRACOR INC. (US) 1995-10-26 WO disclosed
WO-1993009769-A1 METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE SEPRACOR, INC. (US) 1993-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010678-A1 Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers SLC6A4, HTR3A, TPH2 SLC6A4 1/4885SLC6A2 13/4885MEN1 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.